{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T01:37:24Z","timestamp":1793842644894,"version":"4.6.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T00:00:00Z","timestamp":1772496000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":80,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["CA72851, CA181572, CA184792, CA202797, CA227602 and CA296639"],"award-info":[{"award-number":["CA72851, CA181572, CA184792, CA202797, CA227602 and CA296639"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-026-02624-7","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T08:39:37Z","timestamp":1772527177000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["An exosome-based liquid biopsy to predict molecular residual disease for the identification of high-risk patients with stage II-III colorectal cancer: the CLEAR study"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0065-5296","authenticated-orcid":false,"given":"Katsuki","family":"Miyazaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blanca","family":"Montcus\u00ed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Morine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Pascual","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tokunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Noma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Kinugasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Pera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,3]]},"reference":[{"issue":"8","key":"2624_CR1","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40(8):892\u2013910.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2624_CR2","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41591-022-02115-4","volume":"29","author":"D Kotani","year":"2023","unstructured":"Kotani D, Oki E, Nakamura Y, Yukami H, Mishima S, Bando H, et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat Med. 2023;29(1):127\u201334.","journal-title":"Nat Med"},{"issue":"16","key":"2624_CR3","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1200\/JCO.2006.08.6652","volume":"25","author":"SR Land","year":"2007","unstructured":"Land SR, Kopec JA, Cecchini RS, Ganz PA, Wieand HS, Colangelo LH, et al. Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007;25(16):2205\u201311.","journal-title":"J Clin Oncol"},{"key":"2624_CR4","doi-asserted-by":"crossref","unstructured":"Krishnan T, Leung E, Solar Vasconcelos JP, Lim H, Loree JM, Davies J, et al. Three versus six months of adjuvant oxaliplatin-containing chemotherapy for patients with stage III colorectal cancer: a contemporary real-world analysis. JCO Oncol Pract. 2025;21(3):365-72.","DOI":"10.1200\/OP-24-00492"},{"issue":"16","key":"2624_CR5","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1200\/JCO.19.00281","volume":"37","author":"C Lieu","year":"2019","unstructured":"Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Duration of oxaliplatin-containing adjuvant therapy for stage III colon cancer: ASCO clinical practice guideline. J Clin Oncol. 2019;37(16):1436\u201347.","journal-title":"J Clin Oncol"},{"issue":"12","key":"2624_CR6","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020;21(12):1620\u20139.","journal-title":"Lancet Oncol"},{"issue":"33","key":"2624_CR7","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1200\/JCO.21.02962","volume":"40","author":"ST Kim","year":"2022","unstructured":"Kim ST, Kim SY, Lee J, Yun SH, Kim HC, Lee WY, et al. Oxaliplatin (3 months v 6 months) with 6 months of fluoropyrimidine as adjuvant therapy in patients with stage II\/III colon cancer: KCSG CO09-07. J Clin Oncol. 2022;40(33):3868\u201377.","journal-title":"J Clin Oncol"},{"issue":"16","key":"2624_CR8","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1158\/1078-0432.CCR-17-3236","volume":"24","author":"R Kandimalla","year":"2018","unstructured":"Kandimalla R, Gao F, Matsuyama T, Ishikawa T, Uetake H, Takahashi N, et al. Genome-wide discovery and identification of a novel miRNA signature for recurrence prediction in stage II and III colorectal cancer. Clin Cancer Res. 2018;24(16):3867\u201377.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2624_CR9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12943-022-01699-2","volume":"22","author":"K Okuno","year":"2023","unstructured":"Okuno K, Kandimalla R, Mendiola M, Balaguer F, Bujanda L, Fernandez-Martos C, et al. A microRNA signature for risk-stratification and response prediction to FOLFOX-based adjuvant therapy in stage II and III colorectal cancer. Mol Cancer. 2023;22(1):13.","journal-title":"Mol Cancer"},{"issue":"24","key":"2624_CR10","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386(24):2261\u201372.","journal-title":"N Engl J Med"},{"issue":"6","key":"2624_CR11","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1001\/jamaoncol.2023.0425","volume":"9","author":"S Mo","year":"2023","unstructured":"Mo S, Ye L, Wang D, Han L, Zhou S, Wang H, et al. Early detection of molecular residual disease and risk stratification for stage I to III colorectal cancer via circulating tumor DNA methylation. JAMA Oncol. 2023;9(6):770\u20138.","journal-title":"JAMA Oncol"},{"issue":"12","key":"2624_CR12","doi-asserted-by":"publisher","first-page":"e998","DOI":"10.1002\/ctm2.998","volume":"12","author":"T Matsuyama","year":"2022","unstructured":"Matsuyama T, Toiyama Y, Ishikawa T, Okugawa Y, Yasuno M, Maurel J, et al. A metastasis-associated microRNA-based liquid biopsy signature for risk-stratification in colorectal cancer: a multicenter cohort study. Clin Transl Med. 2022;12(12):e998.","journal-title":"Clin Transl Med"},{"key":"2624_CR13","doi-asserted-by":"crossref","unstructured":"Montcus\u00ed B, Madrid-Gambin F, Marin S, Mayol X, Pascual M, Cascante M, et al. Circulating metabolic markers identify patients at risk for tumor recurrence: a prospective cohort study in colorectal cancer surgery. Ann Surg. 2024;1;280(5):842\u20139.","DOI":"10.1097\/SLA.0000000000006463"},{"issue":"3","key":"2624_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1038\/s41416-021-01672-8","volume":"126","author":"S Toden","year":"2022","unstructured":"Toden S, Goel A. Non-coding RNAs as liquid biopsy biomarkers in cancer. Br J Cancer. 2022;126(3):351\u201360.","journal-title":"Br J Cancer"},{"issue":"1","key":"2624_CR15","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12943-022-01556-2","volume":"21","author":"H Zhou","year":"2022","unstructured":"Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection, prognosis, and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86.","journal-title":"Mol Cancer"},{"issue":"11","key":"2624_CR16","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1093\/carcin\/bgaa097","volume":"41","author":"J Ruiz-Ba\u00f1obre","year":"2020","unstructured":"Ruiz-Ba\u00f1obre J, Roy R, Alustiza Fern\u00e1ndez M, Murcia \u00d3, Jover R, Pera M, et al. Clinical significance of a microRNA signature for the identification and predicting prognosis in colorectal cancers with mucinous differentiation. Carcinogenesis. 2020;41(11):1498\u2013506.","journal-title":"Carcinogenesis"},{"key":"2624_CR17","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fonc.2019.00521","volume":"9","author":"F Mannavola","year":"2019","unstructured":"Mannavola F, Salerno T, Passarelli A, Tucci M, Intern\u00f2 V, Silvestris F. Revisiting the role of exosomes in colorectal cancer: where are we now? Front Oncol. 2019;9:521.","journal-title":"Front Oncol"},{"issue":"9","key":"2624_CR18","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1016\/j.apsb.2021.01.001","volume":"11","author":"J Liu","year":"2021","unstructured":"Liu J, Ren L, Li S, Li W, Zheng X, Yang Y, et al. The biology, function, and applications of exosomes in cancer. Acta Pharm Sin B. 2021;11(9):2783\u201397.","journal-title":"Acta Pharm Sin B"},{"issue":"4","key":"2624_CR19","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.annonc.2021.01.074","volume":"32","author":"W Yu","year":"2021","unstructured":"Yu W, Hurley J, Roberts D, Chakrabortty SK, Enderle D, Noerholm M, et al. Exosome-based liquid biopsies in cancer: opportunities and challenges. Ann Oncol. 2021;32(4):466\u201377.","journal-title":"Ann Oncol"},{"issue":"5","key":"2624_CR20","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1053\/j.gastro.2022.06.090","volume":"163","author":"K Nakamura","year":"2022","unstructured":"Nakamura K, Zhu Z, Roy S, Jun E, Han H, Munoz RM, et al. An exosome-based transcriptomic signature for noninvasive, early detection of patients with pancreatic ductal adenocarcinoma: a multicenter cohort study. Gastroenterology. 2022;163(5):1252-66.e2.","journal-title":"Gastroenterology"},{"issue":"1","key":"2624_CR21","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12943-022-01685-8","volume":"22","author":"K Miyazaki","year":"2023","unstructured":"Miyazaki K, Wada Y, Okuno K, Murano T, Morine Y, Ikemoto T, et al. An exosome-based liquid biopsy signature for pre-operative identification of lymph node metastasis in patients with pathological high-risk T1 colorectal cancer. Mol Cancer. 2023;22(1):2.","journal-title":"Mol Cancer"},{"issue":"6","key":"2624_CR22","doi-asserted-by":"publisher","first-page":"e876","DOI":"10.1097\/SLA.0000000000004993","volume":"276","author":"S Nishiwada","year":"2022","unstructured":"Nishiwada S, Cui Y, Sho M, Jun E, Akahori T, Nakamura K, et al. Transcriptomic profiling identifies an exosomal microRNA signature for predicting recurrence following surgery in patients with pancreatic ductal adenocarcinoma. Ann Surg. 2022;276(6):e876\u201385.","journal-title":"Ann Surg"},{"issue":"7","key":"2624_CR23","doi-asserted-by":"publisher","first-page":"e1629","DOI":"10.1002\/ctm2.1629","volume":"14","author":"K Okuno","year":"2024","unstructured":"Okuno K, Watanabe S, Hur H, Lee J, Park JO, Tokunaga M, et al. An exosome-based liquid biopsy signature for therapeutic response prediction in metastatic gastric cancer. Clin Transl Med. 2024;14(7):e1629.","journal-title":"Clin Transl Med"},{"key":"2624_CR24","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.semcancer.2024.02.001","volume":"99","author":"Y Li","year":"2024","unstructured":"Li Y, Sui S, Goel A. Extracellular vesicles associated microRNAs: their biology and clinical significance as biomarkers in gastrointestinal cancers. Semin Cancer Biol. 2024;99:5\u201323.","journal-title":"Semin Cancer Biol"},{"issue":"9","key":"2624_CR25","doi-asserted-by":"publisher","first-page":"5997","DOI":"10.1245\/s10434-024-15592-3","volume":"31","author":"Y Wada","year":"2024","unstructured":"Wada Y, Nishi M, Yoshikawa K, Takasu C, Tokunaga T, Nakao T, et al. Circulating exosomal microRNA signature predicts peritoneal metastasis in patients with advanced gastric cancer. Ann Surg Oncol. 2024;31(9):5997\u20136006.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"2624_CR26","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1158\/1078-0432.CCR-24-1934","volume":"31","author":"C Xu","year":"2025","unstructured":"Xu C, Mannucci A, Esposito F, Oliveres H, Alonso-Ordu\u00f1a V, Yubero A, et al. An exosome-based liquid biopsy predicts depth of response and survival outcomes to cetuximab and panitumumab in metastatic colorectal cancer: the EXONERATE study. Clin Cancer Res. 2025;31(6):1002\u201315.","journal-title":"Clin Cancer Res"},{"key":"2624_CR27","doi-asserted-by":"crossref","unstructured":"Sui S, Xu C, Kanda M, Okugawa Y, Toiyama Y, Park JO, et al. Exosomal liquid biopsy for the early detection of gastric cancer: the DESTINEX multicenter study. JAMA Surg. 2025;160(9):973\u201382.","DOI":"10.1001\/jamasurg.2025.2493"},{"issue":"1","key":"2624_CR28","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41698-025-00978-7","volume":"9","author":"A Mannucci","year":"2025","unstructured":"Mannucci A, Hern\u00e1ndez G, Uetake H, Yamada Y, Balaguer F, Baba H, et al. Prediction of long-term recurrence-free and overall survival in early-onset colorectal cancer: the ENCORE multi-centre study. NPJ Precis Oncol. 2025;9(1):202.","journal-title":"NPJ Precis Oncol"},{"issue":"4","key":"2624_CR29","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1053\/j.gastro.2017.11.275","volume":"154","author":"T Ozawa","year":"2018","unstructured":"Ozawa T, Kandimalla R, Gao F, Nozawa H, Hata K, Nagata H, et al. A MicroRNA signature associated with metastasis of T1 colorectal cancers to lymph nodes. Gastroenterology. 2018;154(4):844-8.e7.","journal-title":"Gastroenterology"},{"issue":"8","key":"2624_CR30","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1053\/j.gastro.2019.02.027","volume":"156","author":"R Kandimalla","year":"2019","unstructured":"Kandimalla R, Ozawa T, Gao F, Wang X, Goel A. Gene expression signature in surgical tissues and endoscopic biopsies identifies high-risk T1 colorectal cancers. Gastroenterology. 2019;156(8):2338-41.e3.","journal-title":"Gastroenterology"},{"issue":"1","key":"2624_CR31","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1053\/j.gastro.2021.03.062","volume":"161","author":"Y Wada","year":"2021","unstructured":"Wada Y, Shimada M, Murano T, Takamaru H, Morine Y, Ikemoto T, et al. A liquid biopsy assay for noninvasive identification of lymph node metastases in T1 colorectal cancer. Gastroenterology. 2021;161(1):151-62.e1.","journal-title":"Gastroenterology"},{"issue":"6","key":"2624_CR32","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1038\/s41416-022-02138-1","volume":"128","author":"K Okuno","year":"2023","unstructured":"Okuno K, Watanabe S, Roy S, Kanda M, Tokunaga M, Kodera Y, et al. A liquid biopsy signature for predicting early recurrence in patients with gastric cancer. Br J Cancer. 2023;128(6):1105\u201316.","journal-title":"Br J Cancer"},{"key":"2624_CR33","doi-asserted-by":"publisher","unstructured":"Noma T, Saez de Gordoa K, Daca-Alvarez M, Miyazaki K, Wada Y, Mannucci A, et al. A machine learning-based transcriptomic signature for predicting tumor recurrence after curative resection in T1 colorectal cancer: a retrospective multicenter cohort study (The Tw1CE trial). Int J Surg. 2026. https:\/\/doi.org\/10.1097\/js9.0000000000004690.","DOI":"10.1097\/js9.0000000000004690"},{"issue":"4","key":"2624_CR34","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1245\/s10434-009-0881-y","volume":"17","author":"NW Wilkinson","year":"2010","unstructured":"Wilkinson NW, Yothers G, Lopa S, Costantino JP, Petrelli NJ, Wolmark N. Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol. 2010;17(4):959\u201366.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"2624_CR35","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s12943-022-01525-9","volume":"21","author":"KA Preethi","year":"2022","unstructured":"Preethi KA, Selvakumar SC, Ross K, Jayaraman S, Tusubira D, Sekar D. Liquid biopsy: exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer. Mol Cancer. 2022;21(1):54.","journal-title":"Mol Cancer"},{"key":"2624_CR36","doi-asserted-by":"crossref","unstructured":"Valencia K, Montuenga LM. Exosomes in liquid biopsy: the nanometric world in the pursuit of precision oncology. Cancers (Basel). 2021;13(9):2147.","DOI":"10.3390\/cancers13092147"},{"issue":"346","key":"2624_CR37","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","volume":"8","author":"J Tie","year":"2016","unstructured":"Tie J, Wang Y, Tomasetti C, Li L, Springer S, Kinde I, et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med. 2016;8(346):346ra92.","journal-title":"Sci Transl Med"},{"issue":"4","key":"2624_CR38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.3892\/ol.2021.12511","volume":"21","author":"X Tian","year":"2021","unstructured":"Tian X, Chang J, Zhang N, Wu S, Liu H, Yu J. Microrna-429 acts as a tumor suppressor in colorectal cancer by targeting high mobility group box 3. Oncol Lett. 2021;21(4):250.","journal-title":"Oncol Lett"},{"issue":"1","key":"2624_CR39","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1089\/omi.2012.0132","volume":"18","author":"Y Sun","year":"2014","unstructured":"Sun Y, Shen S, Tang H, Xiang J, Peng Y, Tang A, et al. Mir-429 identified by dynamic transcriptome analysis is a new candidate biomarker for colorectal cancer prognosis. OMICS. 2014;18(1):54\u201364.","journal-title":"OMICS"},{"issue":"5","key":"2624_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3349\/ymj.2019.60.5.414","volume":"60","author":"J Wan","year":"2019","unstructured":"Wan J, Yang J, Qiao C, Sun X, Di A, Zhang L, et al. MicroRNA-362 inhibits cell proliferation and invasion by directly targeting SIX1 in colorectal cancer. Yonsei Med J. 2019;60(5):414\u201322.","journal-title":"Yonsei Med J"},{"issue":"7","key":"2624_CR41","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1007\/s00432-022-04123-w","volume":"149","author":"M Mahjoor","year":"2023","unstructured":"Mahjoor M, Afkhami H, Najafi M, Nasr A, Khorrami S. The role of microrna-30c in targeting interleukin 6, as an inflammatory cytokine, in the mesenchymal stem cell: a therapeutic approach in colorectal cancer. J Cancer Res Clin Oncol. 2023;149(7):3149\u201360.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"3","key":"2624_CR42","doi-asserted-by":"publisher","first-page":"e0120698","DOI":"10.1371\/journal.pone.0120698","volume":"10","author":"Q Zhang","year":"2015","unstructured":"Zhang Q, Yu L, Qin D, Huang R, Jiang X, Zou C, et al. Role of microrna-30c targeting ADAM19 in colorectal cancer. PLoS ONE. 2015;10(3):e0120698.","journal-title":"PLoS ONE"},{"key":"2624_CR43","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.biopha.2017.12.095","volume":"98","author":"T Ma","year":"2018","unstructured":"Ma T, Zhao Y, Lu Q, Lu Y, Liu Z, Xue T, et al. MicroRNA-30c functions as a tumor suppressor via targeting SNAI1 in esophageal squamous cell carcinoma. Biomed Pharmacother. 2018;98:680\u20136.","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"2624_CR44","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1007\/s10549-012-2346-4","volume":"137","author":"J Bockhorn","year":"2013","unstructured":"Bockhorn J, Yee K, Chang YF, Prat A, Huo D, Nwachukwu C, et al. MicroRNA-30c targets cytoskeleton genes involved in breast cancer cell invasion. Breast Cancer Res Treat. 2013;137(2):373\u201382.","journal-title":"Breast Cancer Res Treat"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-026-02624-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-026-02624-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T23:39:24Z","timestamp":1779406764000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12943-026-02624-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,3]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2624"],"URL":"https:\/\/doi.org\/10.1186\/s12943-026-02624-7","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,3]]},"assertion":[{"value":"5 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent, and the study protocol was approved by the Institutional Review Boards of Tokyo Medical and Dental University and Hospital del Mar.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. The manuscript does not contain any individual personal data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"136"}}